The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Katunina E.A.

Federal Center of Brain and Neurotechnologies;
Pirogov Russian National Research Medical University

Putyatin I.A.

Pirogov Russian National Research Medical University

Dzugaeva F.K.

North Caucasus Multidisciplinary Medical Center

Batsoeva D.O.

North Caucasus Multidisciplinary Medical Center

Epidemiology of Parkinson’s disease

Authors:

Katunina E.A., Putyatin I.A., Dzugaeva F.K., Batsoeva D.O.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(11‑2): 39‑54

DOI: 10.17116/jnevro202512511239

Read: 2434 times

Download PDF (RU)
Contact the author
Table of contents

EPIDEMIOLOGY OF PARKINSON’S DISEASE
EPIDEMIOLOGY OF PARKINSON’S DISEASE

To cite this article:

Katunina EA, Putyatin IA, Dzugaeva FK, Batsoeva DO. Epidemiology of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(11‑2):39‑54. (In Russ.)
https://doi.org/10.17116/jnevro202512511239

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Sleep diso­rders in patients with Lewy body deme­ntia and Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):81-87
Quantitative and nomi­native indi­cators of blood pressure regu­lation violations in the neural network fatal event prediction acco­rding to the prospective obse­rvation. Russian Journal of Preventive Medi­cine. 2025;(4):39-44
Premature birth and obesity: epidemiology, pathogenesis and obstetric tactics. Russian Bulletin of Obstetrician-Gynecologist. 2025;(2):29-34
Art and creativity in Parkinson’s disease: the mysterious effe­cts of dopa­mine. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):13-20
Correlation of motor symptoms and cardiovascular dysfunction in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):59-67
Diagnosis of pathological and adaptive bala­nce changes in Parkinson’s disease to select a reha­bilitation program. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):88-94
Prevalence and characteristics of risk factors for cere­brovascular disease in overweight. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):118-124
Prevalence of postpartum depression in the Russian Fede­ration: a systematic review and meta-analysis. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):74-87
Contribution of the Russian Academy of Sciences Academician R.G. Oganov to the deve­lopment of the dome­stic preventive cardiology. Russian Journal of Preventive Medi­cine. 2025;(6):7-10
Dyna­mics of the main indi­cators of medi­cal care to the popu­lation of the Russian Fede­ration for the period 1993—2023 in the “Oncology” profile. P.A. Herzen Journal of Onco­logy. 2025;(3):71-77
Abstract:

The article discusses key aspects of Parkinson’s disease epidemiology at the global level and in the Russian Federation. The data from modern studies, along with the analysis of trends, indicate a steady increase in key epidemiological indicators, including prevalence, incidence, and mortality. Particular attention is paid to the results of Russian regional epidemiological studies, considering their methodological features and limitations. We consider genetic factors, including the most common ones in the Russian population, as well as other risk factors and protective factors that have a significant impact on the epidemiological landscape of the disease. Also, the challenges associated with the analysis and interpretation of epidemiological studies are addressed.

Keywords:

Parkinson’s disease
epidemiology
prevalence
incidence
risk factors
protective factors

Authors:

Katunina E.A.

Federal Center of Brain and Neurotechnologies;
Pirogov Russian National Research Medical University

Putyatin I.A.

Pirogov Russian National Research Medical University

Dzugaeva F.K.

North Caucasus Multidisciplinary Medical Center

Batsoeva D.O.

North Caucasus Multidisciplinary Medical Center

Received:

11.08.2025

Accepted:

15.08.2025

Close metadata

References:

  1. Luo Y, Qiao L, Li M, et al. Global, regional, national epidemiology and trends of Parkinson’s disease from 1990 to 2021: findings from the Global Burden of Disease Study 2021. Front Aging Neurosci. 2025;16:1498756. https://doi.org/10.3389/fnagi.2024.1498756
  2. Zhu J, Cui Y, Zhang J, et al. Temporal trends in the prevalence of Parkinson’s disease from 1980 to 2023: a systematic review and meta-analysis. Lancet Healthy Longev. 2024;5(7):e464-e479. https://doi.org/10.1016/S2666-7568(24)00094-1
  3. Pringsheim T, Jette N, Frolkis A, et al. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583-1590. https://doi.org/10.1002/mds.25945
  4. Su D, Cui Y, He C, et al. Projections for prevalence of Parkinson’s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. BMJ. 2025;388:e080952. https://doi.org/10.1136/bmj-2024-080952
  5. Li M, Ye X, Huang Z, et al. Global burden of Parkinson’s disease from 1990 to 2021: a population-based study. BMJ Open. 2025;15(4):e095610. https://doi.org/10.1136/bmjopen-2024-095610
  6. Okubadejo NU, Bower JH, Rocca WA, Maraganore DM. Parkinson’s disease in Africa: A systematic review of epidemiologic and genetic studies. Mov Disord. 2006;21(12):2150-2156. https://doi.org/10.1002/mds.21153
  7. Kim DJ, Isidro-Pérez AL, Doering M, et al. Prevalence and Incidence of Parkinson’s Disease in Latin America: A Meta-Analysis. Mov Disord. 2024;39(1):105-118.  https://doi.org/10.1002/mds.29682
  8. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003;157(11):1015-1022. https://doi.org/10.1093/aje/kwg068
  9. Macleod AD, Taylor KS, Counsell CE. Mortality in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1615-1622. https://doi.org/10.1002/mds.25898
  10. Levin OS, Dokadina LV. Epidemiology of parkinsonism and Parkinson’s disease. Neurological J. 2005;10(5):41-49. (In Russ.).
  11. Popova TE, Tappahov AA, Nikolaeva TYa, et al. Epidemiology of Parkinson’s disease in the Republic of Sakha (Yakutia). Yakutskij medicinskij zhurnal. 2017;3(59).98-101. (In Russ.).
  12. Krivonos OV. The regional model of organization of medical care to patients with Parkinson disease in modern socioeconomic conditions. Saratov Journal of Medical Scientific Research. 2013;9(4).867-869. (In Russ.).
  13. Sichinava DK, Bonzyuk LI, Kurynnaya EA, et al. Clinical and epidemiological characteristics for parkinsonism and Parkinson’s disease in Krasnodar region. Innovative Medicine of Kuban. 2017;7(3):38-40. (In Russ.).
  14. Kurapin EV, Bykanova MA, Trofimova NV. The results of the 10-year experience of a regional center of care for patients with Parkinsonism and extrapyramidal pathology in Yaroslavl and Yaroslavl region. Annals of clinical and experimental neurology. 2018;12(2):12-21. (In Russ.). https://doi.org/10.18454/ACEN.2018.2.2
  15. Sapronova MR, Shnaider NA. The epidemiological, clinical, and genetic characteristics of Parkinson’s disease (in case of Zheleznogorsk). Neurology, Neuropsychiatry, Psychosomatics. 2014;(4):59-64 (In Russ.). https://doi.org/10.14412/2074-2711-2014-4-59-64
  16. Strachunskaya EYa. Parkinsonizm s pozicij sovremennyh informacionnyh koncepcij mediciny. Smolensk: SGMA; 2008. (In Russ.).
  17. Pokhabov DV, Abramov VG, Nesterova YV. Epidemiology of parkinsonism in the Krasnoyarsk region. Annaly klinicheskoj i eksperimental’noj nevrologii. 2017;2(4):4-9 (In Russ.).
  18. Sayutina SB, Shprakh VV, Valiulin MA, et al. Diagnostics and treatment problems of Parkinson’s disease in Irkutsk region. Sibirskij medicinskij zhurnal. 2009;110 (7):173-175. (In Russ.).
  19. Katunina EA, Avakyan GN, Bezdol’nyi IuN, et al. Epidemiology of Parkinson’s disease. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2009;109 (11):76-80. (In Russ.).
  20. Kalashnikova OS, Munasipova SE, Khasanova DM, et al. Epidemiology of Parkinson’s disease in the Republic of Tatarstan. Prakticheskaya medicina. 2011;55:210-21. (In Russ.).
  21. Vasilenko AF, Shamurov YuS, Kostenkova LYu. Parkinson’s disease in general practitioner activity: clinical diagnostic approaches. Medicinskij vestnik Bashkortostana. 2010;5(6):35-39 (In Russ.).
  22. Razdorskaya VV, Voskresenskaya ON, Yudina GK. The diagnostic reliability of outpatient neurological care to patients with Parkinson’s disease. Saratov Journal of Medical Scientific Research. 2012;8(2):513-517. (In Russ.).
  23. Antonen EG. Kliniko-epidemiologicheskaya harakteristika parkinsonizma v Respublike Kareliya. Petrozavodsk: Izdatel’stvo PetrGU, 2016. (In Russ.).
  24. Goncharova ZA, Rabadanova EA, Gelpey MA. Epidemiology analysis of Parkinson’s disease in Rostov-on-Don. Saratov Journal of Medical Scientific Research. 2017;13(1): 135-139. (In Russ.).
  25. Bogdanov RR, Kotov SV. Prevalence of Parkinson’s Disease in Moscow Region. Doctor.Ru. Neurology Psychiatry. 2016;4 (121):5-9 (In Russ.).
  26. Efimenko EYu. Epidemiological analysis of Parkinson’s disease in Krasnodar. Lechaschi Vrach. 2025;4(28):49-53. (In Russ.). https://doi.org/10.51793/OS.2025.28.4.007
  27. Lange LM, Gonzalez-Latapi P, Rajalingam R, et al. Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force — An Update. Mov Disord. 2022;37(5):905-935.  https://doi.org/10.1002/mds.28982
  28. Konovalova EV, Lopacheva OM, Grivennikov IA, et al. Mutations in the Parkinson’s Disease-Associated PARK2 Gene Are Accompanied by Imbalance in Programmed Cell Death Systems. Acta Naturae. 2015;7(4):146-149. 
  29. Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18(12):1091-1102. https://doi.org/10.1016/S1474-4422(19)30320-5
  30. Berg D, Niwar M, Maass S, et al. Alpha-synuclein and Parkinson’s disease: implications from the screening of more than 1,900 patients. Mov Disord. 2005;20(9):1191-1194. https://doi.org/10.1002/mds.20504
  31. Lesage S, Brice A. Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet. 2009;18(R1):R48-R59.  https://doi.org/10.1093/hmg/ddp012
  32. Alieva AK, Shadrina MI, Filatova EV, et al. Polymorphisms in the SNCA gene: association with the risk of development of the sporadic form of Parkinson’s disease and the level of SNCA gene expression in peripheral blood of patients from Russia. Neurosci Med. 2013;4:208-214.  https://doi.org/10.4236/nm.2013.44032
  33. Kilarski LL, Pearson JP, Newsway V, et al. Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson’s disease. Mov Disord. 2012;27(12):1522-1529. https://doi.org/10.1002/mds.25132
  34. Illarioshkin SN, Slominsky PA, Shadrina MI, et al. Heterogeneity of sporadic Parkinson’s disease: molecular approach to solving the problem. Annaly klinicheskoj i eksperimental’noj nevrologii. 2007;1(1):23-31. (In Russ.).
  35. Emelyanov AK, Usenko TS, Tesson C, et al. Mutation analysis of Parkinson’s disease genes in a Russian data set. Neurobiol Aging. 2018;71:267.e7-267.e10.  https://doi.org/10.1016/j.neurobiolaging.2018.06.027
  36. Healy DG, Falchi M, O’Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol. 2008;7(7):583-590.  https://doi.org/10.1016/S1474-4422(08)70117-0
  37. Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol. 2012;11(11):986-998.  https://doi.org/10.1016/S1474-4422(12)70190-4
  38. Gan’kina OA, Vasenina EE, Levin OS, et al. Characteristics of Parkinson’s disease course in the heterozygous carriage of mutations in the glucocerebrosidase A gene. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2016;116(6-2):71-76. (In Russ.). https://doi.org/10.17116/jnevro20161166271-76
  39. Pchelina SN, Ivanova ON, Emel’ianov AK, Iakimovskiĭ AF. Clinical features of LRRK2-associated Parkinson’s disease. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2011;111(12):56-62. (In Russ.).
  40. llarioshkin SN, Shadrina MI, Slominsky PA, et al. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson’s disease In Russia. Eur J Neurol. 2007;14(4):413-417.  https://doi.org/10.1111/j.1468-1331.2007.01685.x
  41. Semenova EV, Shadrina MI, Slominsky PA, et al. Analysis of PARK2 gene exon rearrangements In Russian patients with sporadic Parkinson’s disease. Mov Disord. 2012;27(1):139-142.  https://doi.org/10.1002/mds.23901
  42. Shulskaya MV, Shadrina MI, Fedotova EY, et al. Second mutation in PARK2 is absent in patients with sporadic Parkinson’s disease and heterozygous exonic deletions/duplications in parkin gene. Int J Neurosci. 2017;127(9):781-784.  https://doi.org/10.1080/00207454.2016.1255612
  43. Senkevich KA, Miliukhina IV, Beletskaia MV, et al. The clinical features of Parkinson’s disease in patients with mutations and polymorphic variants of GBA gene. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2017;117(10):81-86. (In Russ.). https://doi.org/10.17116/jnevro201711710181-86
  44. Emelyanov A, Boukina T, Yakimovskii A, et al. Glucocerebrosidase gene mutations are associated with Parkinson’s disease In Russia. Mov Disord. 2012;27(1):158-159.  https://doi.org/10.1002/mds.23950
  45. Abramycheva NY, Fedotova EY, Stepanova MS, et al. New approach to molecular and genetic screening of patients with Parkinson’s disease. Nevrologicheskij zhurnal. 2016;21(1):13-16. (In Russ.).
  46. Subbotina TN, Abramov VG, Razumova AA, et al. Analysis of mutations associated with Parkinson’s disease in patients of the Krasnoyarsk region. Rossijskij nevrologicheskij zhurnal. 2021;26(4):15-22. (In Russ.). https://doi.org/10.30629/2658-7947-2021-26-4-15-22
  47. Filatova EV, Alieva AH, Shadrina MI. Analysis of Mutations in Patients with Suspected Autosomal Dominant Form of the Parkinson Disease. Molekulyarnaya genetika, mikrobiologiya i virusologiya. 2014;1:3-4. (In Russ.).
  48. Hirsch L, Jette N, Frolkis A, et al. The Incidence of Parkinson’s Disease: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2016;46(4):292-300.  https://doi.org/10.1159/000445751
  49. Taylor KS, Cook JA, Counsell CE. Heterogeneity in male to female risk for Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78(8):905-906.  https://doi.org/10.1136/jnnp.2006.104695
  50. Jurado-Coronel JC, Cabezas R, Ávila Rodríguez MF, et al. Sex differences in Parkinson’s disease: Features on clinical symptoms, treatment outcome, sexual hormones and genetics. Front Neuroendocrinol. 2018;50:18-30.  https://doi.org/10.1016/j.yfrne.2017.09.002
  51. Haaxma CA, Bloem BR, Borm GF, et al. Gender differences in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78(8):819-824.  https://doi.org/10.1136/jnnp.2006.103788
  52. Lv M, Zhang Y, Chen GC, et al. Reproductive factors and risk of Parkinson’s disease in women: A meta-analysis of observational studies. Behav Brain Res. 2017;335:103-110.  https://doi.org/10.1016/j.bbr.2017.07.025
  53. MacAskill MR, Myall DJ, Shoorangiz R, et al. Childbirth and Delayed Parkinson’s Onset: A Reproducible Nonbiological Artifact of Societal Change. Mov Disord. 2020;35(7):1268-1271. https://doi.org/10.1002/mds.28135
  54. Barbeau A, Roy M, Bernier G, et al. Ecogenetics of Parkinson’s disease: prevalence and environmental aspects in rural areas. Can J Neurol Sci. 1987;14(1):36-41.  https://doi.org/10.1017/s0317167100026147
  55. Svenson LW, Platt GH, Woodhead SE. Geographic variations in the prevalence rates of Parkinson’s disease in Alberta. Can J Neurol Sci. 1993;20(4):307-311. 
  56. Gatto NM, Cockburn M, Bronstein J, et al. Well-water consumption and Parkinson’s disease in rural California. Environ Health Perspect. 2009;117(12):1912-1918. https://doi.org/10.1289/ehp.0900852
  57. Shi Y, Zhang K, Ye M. Well-Water Consumption and Risk of Parkinson’s Disease: A Meta-Analysis of 15 Observational Studies. Neuropsychiatr Dis Treat. 2021;17:3705-3714. https://doi.org/10.2147/NDT.S336939
  58. Gunnarsson LG, Bodin L. Occupational Exposures and Neurodegenerative Diseases-A Systematic Literature Review and Meta-Analyses. Int J Environ Res Public Health. 2019;16(3):337.  https://doi.org/10.3390/ijerph16030337
  59. Tanner CM, Kamel F, Ross GW, et al. Rotenone, paraquat, and Parkinson’s disease. Environ Health Perspect. 2011;119(6):866-872.  https://doi.org/10.1289/ehp.1002839
  60. Goldman SM, Quinlan PJ, Ross GW, et al. Solvent exposures and Parkinson disease risk in twins. Ann Neurol. 2012;71(6):776-784.  https://doi.org/10.1002/ana.22629
  61. Gatto NM, Rhodes SL, Manthripragada AD, et al. α-Synuclein gene may interact with environmental factors in increasing risk of Parkinson’s disease. Neuroepidemiology. 2010;35(3):191-195.  https://doi.org/10.1159/000315157
  62. Rybicki BA, Johnson CC, Uman J, Gorell JM. Parkinson’s disease mortality and the industrial use of heavy metals in Michigan. Mov Disord. 1993;8(1):87-92.  https://doi.org/10.1002/mds.870080116
  63. Weisskopf MG, Weuve J, Nie H, et al. Association of cumulative lead exposure with Parkinson’s disease. Environ Health Perspect. 2010;118(11):1609-1613. https://doi.org/10.1289/ehp.1002339
  64. Hu CY, Fang Y, Li FL, et al. Association between ambient air pollution and Parkinson’s disease: Systematic review and meta-analysis. Environ Res. 2019;168:448-459.  https://doi.org/10.1016/j.envres.2018.10.008
  65. Leta V, Urso D, Batzu L, et al. Viruses, parkinsonism and Parkinson’s disease: the past, present and future. J Neural Transm (Vienna). 2022;129(9):1119-1132. https://doi.org/10.1007/s00702-022-02536-y
  66. Wang H, Liu X, Tan C, et al. Bacterial, viral, and fungal infection-related risk of Parkinson’s disease: Meta-analysis of cohort and case-control studies. Brain Behav. 2020;10(3):e01549. https://doi.org/10.1002/brb3.1549
  67. Jang H, Boltz D, Sturm-Ramirez K, et al. Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc Natl Acad Sci U S A. 2009;106(33):14063-14068. https://doi.org/10.1073/pnas.0900096106
  68. Toovey S, Jick SS, Meier CR. Parkinson’s disease or Parkinson symptoms following seasonal influenza. Influenza Other Respir Viruses. 2011;5(5):328-333.  https://doi.org/10.1111/j.1750-2659.2011.00232.x
  69. Zhao H, Zhou X, Fu K, et al. Prospective cohort study evaluating the association between influenza vaccination and neurodegenerative diseases. NPJ Vaccines. 2024;9(1):51.  https://doi.org/10.1038/s41541-024-00841-z
  70. Harris MA, Tsui JK, Marion SA, et al. Association of Parkinson’s disease with infections and occupational exposure to possible vectors. Mov Disord. 2012;27(9):1111-1117. https://doi.org/10.1002/mds.25077
  71. Cocoros NM, Svensson E, Szépligeti SK, et al. Long-term Risk of Parkinson Disease Following Influenza and Other Infections. JAMA Neurol. 2021;78(12):1461-1470. https://doi.org/10.1001/jamaneurol.2021.3895
  72. Pakpoor J, Noyce A, Goldacre R, et al. Viral hepatitis and Parkinson disease: A national record-linkage study. Neurology. 2017;88(17):1630-1633. https://doi.org/10.1212/WNL.0000000000003848
  73. Wu WY, Kang KH, Chen SL, et al. Hepatitis C virus infection: a risk factor for Parkinson’s disease. J Viral Hepat. 2015;22(10):784-791.  https://doi.org/10.1111/jvh.12392
  74. Su TH, Yang HC, Tseng TC, et al. Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism. Mov Disord. 2019;34(12):1882-1890. https://doi.org/10.1002/mds.27848
  75. Lin WY, Lin MS, Weng YH, et al. Association of Antiviral Therapy With Risk of Parkinson Disease in Patients With Chronic Hepatitis C Virus Infection. JAMA Neurol. 2019;76(9):1019-1027. https://doi.org/10.1001/jamaneurol.2019.1368
  76. McGee DJ, Lu XH, Disbrow EA. Stomaching the Possibility of a Pathogenic Role for Helicobacter pylori in Parkinson’s Disease. J Parkinsons Dis. 2018;8(3):367-374.  https://doi.org/10.3233/JPD-181327
  77. Fearon C, Fasano A. Parkinson’s Disease and the COVID-19 Pandemic. J Parkinsons Dis. 2021;11(2):431-444.  https://doi.org/10.3233/JPD-202320
  78. Calculli A, Bocci T, Porcino M, et al. Parkinson disease following COVID-19: Report of six cases. Eur J Neurol. 2023;30(5):1272-1280. https://doi.org/10.1111/ene.15732
  79. Taquet M, Sillett R, Zhu L, et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry. 2022;9(10):815-827.  https://doi.org/10.1016/S2215-0366(22)00260-7
  80. Jafari S, Etminan M, Aminzadeh F, Samii A. Head injury and risk of Parkinson disease: a systematic review and meta-analysis. Mov Disord. 2013;28(9):1222-1229. https://doi.org/10.1002/mds.25458
  81. Rugbjerg K, Ritz B, Korbo L, et al. Risk of Parkinson’s disease after hospital contact for head injury: population based case-control study. BMJ. 2008;337:a2494. https://doi.org/10.1136/bmj.a2494
  82. Fang F, Chen H, Feldman AL, et al. Head injury and Parkinson’s disease: a population-based study. Mov Disord. 2012;27(13):1632-1635. https://doi.org/10.1002/mds.25143
  83. Gao J, Liu R, Zhao E, et al. Head injury, potential interaction with genes, and risk for Parkinson’s disease. Parkinsonism Relat Disord. 2015;21(3):292-296.  https://doi.org/10.1016/j.parkreldis.2014.12.033
  84. Taylor KM, Saint-Hilaire MH, Sudarsky L, et al. Head injury at early ages is associated with risk of Parkinson’s disease. Parkinsonism Relat Disord. 2016;23:57-61.  https://doi.org/10.1016/j.parkreldis.2015.12.005
  85. Goldman SM, Kamel F, Ross GW, et al. Head injury, α-synuclein Rep1, and Parkinson’s disease. Ann Neurol. 2012;71(1):40-48.  https://doi.org/10.1002/ana.22499
  86. Yahalom G, Rigbi A, Israeli-Korn S, et al. Age at Onset of Parkinson’s Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations. J Parkinsons Dis. 2020;10(3):1123-1132. https://doi.org/10.3233/JPD-191829
  87. Jiang W, Ju C, Jiang H, Zhang D. Dairy foods intake and risk of Parkinson’s disease: a dose-response meta-analysis of prospective cohort studies. Eur J Epidemiol. 2014;29(9):613-619.  https://doi.org/10.1007/s10654-014-9921-4
  88. Abbott RD, Ross GW, Petrovitch H, et al. Midlife milk consumption and substantia nigra neuron density at death. Neurology. 2016;86(6):512-519.  https://doi.org/10.1212/WNL.0000000000002254
  89. Brudek T. Inflammatory Bowel Diseases and Parkinson’s Disease. J Parkinsons Dis. 2019;9(s2):S331-S344. https://doi.org/10.3233/JPD-191729
  90. Svensson E, Horváth-Puhó E, Thomsen RW, et al. Vagotomy and subsequent risk of Parkinson’s disease. Ann Neurol. 2015;78(4):522-529.  https://doi.org/10.1002/ana.24448
  91. Mertsalmi TH, Pekkonen E, Scheperjans F. Antibiotic exposure and risk of Parkinson’s disease in Finland: A nationwide case-control study. Mov Disord. 2020;35(3):431-442.  https://doi.org/10.1002/mds.27924
  92. Zhu F, Li C, Gong J, et al. The risk of Parkinson’s disease in inflammatory bowel disease: A systematic review and meta-analysis. Dig Liver Dis. 2019;51(1):38-42.  https://doi.org/10.1016/j.dld.2018.09.017
  93. Herrick MK, Tansey MG. Is LRRK2 the missing link between inflammatory bowel disease and Parkinson’s disease? NPJ Parkinsons Dis. 2021;7(1):26.  https://doi.org/10.1038/s41531-021-00170-1
  94. Chohan H, Senkevich K, Patel RK, et al. Type 2 Diabetes as a Determinant of Parkinson’s Disease Risk and Progression. Mov Disord. 2021;36(6):1420-1429. https://doi.org/10.1002/mds.28551
  95. Ribarič S. The Contribution of Type 2 Diabetes to Parkinson’s Disease Aetiology. Int J Mol Sci. 2024;25(8):4358. https://doi.org/10.3390/ijms25084358
  96. Zhong Y, Wang TH, Huang LJ, Hua YS. Association between metabolic syndrome and the risk of Parkinson’s disease: a meta-analysis. BMC Neurol. 2024;24(1):313.  https://doi.org/10.1186/s12883-024-03820-y
  97. Gao X, Simon KC, Han J, et al. Genetic determinants of hair color and Parkinson’s disease risk. Ann Neurol. 2009;65(1):76-82.  https://doi.org/10.1002/ana.21535
  98. Cheng P, Yu J, Huang W, et al. Dietary intake of iron, zinc, copper, and risk of Parkinson’s disease: a meta-analysis. Neurol Sci. 2015;36(12):2269-2275. https://doi.org/10.1007/s10072-015-2349-0
  99. Zhang R, Shu L, Zhu Q, Li N. Adherence to a priori and a posteriori dietary patterns and risk of Parkinson’s disease: a systematic review and meta-analysis of observational studies. Front Nutr. 2025;12:1600955. https://doi.org/10.3389/fnut.2025.1600955
  100. Pezzoli G, Cereda E. Exposure to pesticides or solvents and risk of Parkinson disease. Neurology. 2013;80(22):2035-2041. https://doi.org/10.1212/WNL.0b013e318294b3c8
  101. Li X, Li W, Liu G, et al. Association between cigarette smoking and Parkinson’s disease: A meta-analysis. Arch Gerontol Geriatr. 2015;61(3):510-516.  https://doi.org/10.1016/j.archger.2015.08.004
  102. Lin X, Li Q, Pu M, et al. Significance of nicotine and nicotinic acetylcholine receptors in Parkinson’s disease. Front Aging Neurosci. 2025;17:1535310. https://doi.org/10.3389/fnagi.2025.1535310
  103. Villafane G, Thiriez C, Audureau E, et al. High-dose transdermal nicotine in Parkinson’s disease patients: a randomized, open-label, blinded-endpoint evaluation phase 2 study. Eur J Neurol. 2018;25(1):120-127.  https://doi.org/10.1111/ene.13474
  104. Ritz B, Lee PC, Lassen CF, Arah OA. Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease. Neurology. 2014;83(16):1396-1402. https://doi.org/10.1212/WNL.0000000000000879
  105. Larsson SC, Burgess S. Appraising the causal role of smoking in multiple diseases: A systematic review and meta-analysis of Mendelian randomization studies. EBioMedicine. 2022;82:104154. https://doi.org/10.1016/j.ebiom.2022.104154
  106. Chen JF, Schwarzschild MA. Do caffeine and more selective adenosine A2A receptor antagonists protect against dopaminergic neurodegeneration in Parkinson’s disease? Parkinsonism Relat Disord. 2020;80 Suppl 1(Suppl 1):S45-S53.  https://doi.org/10.1016/j.parkreldis.2020.10.024
  107. Kim IY, O’Reilly ÉJ, Hughes KC, et al. Differences in Parkinson’s Disease Risk with Caffeine Intake and Postmenopausal Hormone Use. J Parkinsons Dis. 2017;7(4):677-684.  https://doi.org/10.3233/JPD-171175
  108. Qi H, Li S. Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson’s disease. Geriatr Gerontol Int. 2014;14(2):430-439.  https://doi.org/10.1111/ggi.12123
  109. Crotty GF, Maciuca R, Macklin EA, et al. Association of caffeine and related analytes with resistance to Parkinson disease among LRRK2 mutation carriers: A metabolomic study. Neurology. 2020;95(24):e3428-e3437. https://doi.org/10.1212/WNL.0000000000010863
  110. Jiang Y, Zhang S, Chen Y, et al. Physical activity and risk of Parkinson’s disease: an updated systematic review and meta-analysis. J Neurol. 2024;271(12):7434-7459. https://doi.org/10.1007/s00415-024-12672-y
  111. Xu Q, Park Y, Huang X, et al. Physical activities and future risk of Parkinson disease. Neurology. 2010;75(4):341-348.  https://doi.org/10.1212/WNL.0b013e3181ea1597
  112. Gao X, O’Reilly ÉJ, Schwarzschild MA, Ascherio A. Prospective study of plasma urate and risk of Parkinson disease in men and women. Neurology. 2016;86(6):520-526.  https://doi.org/10.1212/WNL.0000000000002351
  113. Shen C, Guo Y, Luo W, et al. Serum urate and the risk of Parkinson’s disease: results from a meta-analysis. Can J Neurol Sci. 2013;40(1):73-79.  https://doi.org/10.1017/s0317167100012981
  114. Wen M, Zhou B, Chen YH, et al. Serum uric acid levels in patients with Parkinson’s disease: A meta-analysis. PLoS One. 2017;12(3):e0173731. https://doi.org/10.1371/journal.pone.0173731
  115. Seifar F, Dinasarapu AR, Jinnah HA. Uric Acid in Parkinson’s Disease: What Is the Connection?. Mov Disord. 2022;37(11):2173-2183. https://doi.org/10.1002/mds.29209
  116. Zhang D, Jiang H, Xie J. Alcohol intake and risk of Parkinson’s disease: a meta-analysis of observational studies. Mov Disord. 2014;29(6):819-822.  https://doi.org/10.1002/mds.25863
  117. Boulos C, Yaghi N, El Hayeck R, et al. Nutritional Risk Factors, Microbiota and Parkinson’s Disease: What Is the Current Evidence?. Nutrients. 2019;11(8):1896. https://doi.org/10.3390/nu11081896
  118. Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, et al. Alcohol consumption and risk for Parkinson’s disease: a systematic review and meta-analysis. J Neurol. 2019;266(8):1821-1834. https://doi.org/10.1007/s00415-018-9032-3
  119. Li M, Zhang X, Chen K, et al. Alcohol Exposure and Disease Associations: A Mendelian Randomization and Meta-Analysis on Weekly Consumption and Problematic Drinking. Nutrients. 2024;16(10):1517. https://doi.org/10.3390/nu16101517
  120. Xu TX, Jiang HY, Yang ZY. Renin-angiotensin system inhibitor use and risk of Parkinson’s disease: a meta-analysis. Acta Neurol Belg. 2025;125(1):53-60.  https://doi.org/10.1007/s13760-024-02560-7
  121. Lin J, Pang D, Li C, et al. Calcium channel blockers and Parkinson’s disease: a systematic review and meta-analysis. Ther Adv Neurol Disord. 2024;17:17562864241252713. https://doi.org/10.1177/17562864241252713
  122. Yan J, Qiao L, Tian J, et al. Effect of statins on Parkinson’s disease: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(12):e14852. https://doi.org/10.1097/MD.0000000000014852
  123. Racette BA, Gross A, Vouri SM, et al. Immunosuppressants and risk of Parkinson disease. Ann Clin Transl Neurol. 2018;5(7):870-875.  https://doi.org/10.1002/acn3.580
  124. Ren L, Yi J, Yang J, et al. Nonsteroidal anti-inflammatory drugs use and risk of Parkinson disease: A dose-response meta-analysis. Medicine (Baltimore). 2018;97(37):e12172. https://doi.org/10.1097/MD.0000000000012172
  125. Szmigiel A, da Rocha MM, Browne K, et al. Association Between β-Adrenoreceptor Agonists and Antagonists and Parkinson’s Disease: Systematic Review and Meta-Analysis. Pharmacoepidemiol Drug Saf. 2025;34(4):e70140. https://doi.org/10.1002/pds.70140
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.